#USA #Atlanta #Airway Therapeutics #Zelpultide Alfa #Bronchopulmonary Dysplasia

Airway Therapeutics Secures Significant Funding for Clinical Development of Zelpultide Alfa

Airway Therapeutics, Inc., a prominent player in the field of biopharmaceuticals, has announced a successful close of an equity round amounting to $50 million. This investment is set to facilitate the critical late-stage clinical trials of their innovative biologic therapy, zelpultide alfa, which targets high-risk preterm infants at risk of developing bronchopulmonary dysplasia (BPD).

The funding structure consists of $26 million from earlier SAFE financing and an additional $24 million raised through the Series E-2 round. Notably, about 94% of existing investors partook in this latest round, showcasing their confidence in the company's vision and its ongoing projects. Hopeful participants include Cincinnati Children's and various family office syndicates, united in their intent to support groundbreaking therapies targeting severe respiratory conditions.

Dr. Marc Salzberg, the Chairman and CEO of Airway Therapeutics, expressed satisfaction with the overwhelming support from existing investors. He emphasized that their commitment reinforces the potential of zelpultide alfa and aligns with the company's goal of addressing urgent medical needs in vulnerable infant populations. "We are well-positioned to advance our late-stage clinical program as we pursue preventive therapies for BPD, a significant unmet medical challenge,' he remarked.

The ongoing Phase 2b/3 clinical trial is a pivotal part of this initiative, with the first interim analysis of Phase 2b expected by the close of the second quarter in 2027. This analysis is crucial to assess the safety and efficacy of zelpultide alfa, which is engineered to replicate the native human surfactant protein D (rhSP-D). By modulating immune responses, enhancing pathogen recognition, and maintaining surfactant homeostasis, zelpultide alfa offers a multifaceted approach to ameliorating respiratory conditions.

The potential impact of zelpultide alfa extends beyond just preterm infants, as it is under development for a variety of respiratory, inflammatory, and infectious conditions across all age groups. This broad applicability highlights the biologic's versatility and underscores Airway Therapeutics' commitment to revolutionizing patient care in respiratory health.

As the company charts its course through the challenges of clinical development, the funds from this equity round also guarantee resources to refine analytical processes and build readiness for future regulatory submissions. CFO Alan S. Wolk emphasized the significance of solid financial backing in navigating the complexities of clinical trials effectively, ensuring that every facet of the development process remains on track.

In summary, Airway Therapeutics stands at the forefront of innovation within the biopharmaceutical landscape, armed with new funding that propels its clinical aspirations for zelpultide alfa. By pursuing ambitious research and development goals, the company aims to transform the way serious respiratory diseases, particularly BPD, are treated and ultimately improve health outcomes for some of the most vulnerable patients in the healthcare system.

For more information about their development programs and updates, visit Airway Therapeutics.